Clinical trials: T-Cell Acute Lymphoblastic Lymphoma
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and…
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
- Trial name
- NCT04088864
- Testing
- Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kara Lynn Davis
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- NCT06635330
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Kara Yakhteh Tajhiz Azma Company
B-cell Leukemia
CAR-T Immunotherapy Targeting CD19- ALL
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients…
- Trial name
- NCT04016129
- Testing
- 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed Acute Lymphoblastic Leukemia (ALL)
CAR-T Cell Therapy for ALL
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and the second most frequent acute leukemia in adults. B-cell ALL constitutes approximately 85% of all ALL diagnoses.
- Trial name
- PAKCAR-ALL (NCT07695012)
- Testing
- CAR-T cell infusion
- Where
- Pakistan
- Volunteers
- 10 people
- Sponsor
- Dr. Zaineb Akram
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of BMS-214662 in treating patients who have acute leukemia, myelodysplastic…
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes
- Trial name
- NCT00006213
- Testing
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Mantle Cell Lymphoma
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis.
- Conditions
- Leukemia, Mantle Cell Lymphoma, Myelofibrosis
- Trial name
- NCT00081874
- Testing
- RAD001
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes
- Trial name
- NCT00005622
- Testing
- cyclophosphamide, TBI
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
- Trial name
- NCT00005802
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
U69-CART-Cells For R/R T-ALL
Overall Introduction This single-arm, open-label clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection (CXCR4 CCR9 CAR-T)…
- Trial name
- NCT07350863
- Testing
- CXCR4 CCR9 CAR-T
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Acute Lymphoblastic Leukemia
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42…
- Trial name
- NCT06408194
- Testing
- CD22CART infusion, Tisagenlecleucel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
B-cell Acute Lymphoblastic Leukemia
CD19-CAR-T Cells in Patients With R/R B-ALL
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells")…
- Trial name
- NCT03574168
- Testing
- CD19-CAR-T Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Bioceltech Therapeutics, Ltd.
Leukemia, Myelodysplastic Syndromes
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00996047
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Where
- 280 sites in United States
- Volunteers
- 3,341 people
- Sponsor
- SWOG Cancer Research Network
Acute Lymphocytic Leukemia
Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia
This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Senl_1904A and Senl_1904B) targeting cluster of differentiation antigen 19…
- Trial name
- NCT03840317
- Testing
- Autologous CD19-targeting CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Chronic Myeloproliferative Disorders, Leukemia
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00293410
- Testing
- clofarabine, cyclophosphamide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- NCT03097770
- Testing
- anti-CD19/20-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
This study aims at evaluating the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B-cell surface antigen CD19…
- Conditions
- Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
- Trial name
- NCT04787263
- Testing
- CD19-CAR_Lenti T cell
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Bambino Gesù Hospital and Research Institute